Compare BCE & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCE | TEVA |
|---|---|---|
| Founded | 1880 | 1901 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | BCE | TEVA |
|---|---|---|
| Price | $23.56 | $28.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $29.50 | $27.00 |
| AVG Volume (30 Days) | 2.9M | ★ 11.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | ★ 7324.86 | N/A |
| EPS | ★ 4.80 | 0.62 |
| Revenue | ★ $17,579,277,614.00 | $16,776,000,000.00 |
| Revenue This Year | $1.89 | $4.74 |
| Revenue Next Year | $3.03 | $0.48 |
| P/E Ratio | ★ $4.95 | $46.12 |
| Revenue Growth | ★ 0.11 | 0.02 |
| 52 Week Low | $20.28 | $12.47 |
| 52 Week High | $27.28 | $28.68 |
| Indicator | BCE | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 80.93 |
| Support Level | $23.10 | $24.01 |
| Resistance Level | $23.77 | $26.96 |
| Average True Range (ATR) | 0.39 | 0.68 |
| MACD | 0.07 | 0.19 |
| Stochastic Oscillator | 86.45 | 94.65 |
BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to HBO Max and Starz.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.